

CITATION REPORT

List of articles citing

Progressive multiple sclerosis: pathology and pathogenesis

DOI: 10.1038/nrneurol.2012.168

Nature Reviews Neurology, 2012, 8, 647-56.

Source: <https://exaly.com/paper-pdf/54026764/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
719	Neuroinflammation as the proximate cause of signature pathogenic pattern progression in amyotrophic lateral sclerosis, AIDS, and multiple sclerosis. 2012 , 2012, 169270		7
718	Ion channels boost axonal injury in multiple sclerosis. 2012 , 18, 1743-5		5
717	Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14/TRAIL. 2013 , 10, 36		16
716	Treatment trials in progressive MS--current challenges and future directions. <i>Nature Reviews Neurology</i> , 2013 , 9, 496-503	15	35
715	Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects. 2013 , 15, 241-58		19
714	Neuroprotection in multiple sclerosis: a therapeutic approach. 2013 , 27, 799-815		14
713	An electrophysiologic approach to quantify impaired synaptic transmission and plasticity in experimental autoimmune encephalomyelitis. 2013 , 264, 48-53		17
712	The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations. 2013 , 110, 1-47		59
711	Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model. 2013 , 2, 797-807		58
710	Disease-modifying treatments for progressive multiple sclerosis. 2013 , 19, 1428-36		38
709	Synthesis and characterization of a novel gadolinium-based contrast agent for magnetic resonance imaging of myelination. 2013 , 56, 1629-40		14
708	Oligodendroglia and neurotrophic factors in neurodegeneration. 2013 , 29, 216-28		40
707	New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis. 2013 , 9, 423-40		15
706	Modeling the heterogeneity of multiple sclerosis in animals. 2013 , 34, 410-22		128
705	Dimethyl fumarate: a novel oral front-line therapy for multiple sclerosis treatment. 2013 , 8, 247-254		4
704	Disease-specific molecular events in cortical multiple sclerosis lesions. 2013 , 136, 1799-815		198
703	Iron and neurodegeneration in the multiple sclerosis brain. 2013 , 74, 848-61		304

702	Multiple sclerosis: does Nogo play a role?. 2013 , 19, 394-408	26
701	Immune cells perturb axons and impair neuronal survival in a mouse model of infantile neuronal ceroid lipofuscinosis. 2013 , 136, 1083-101	42
700	Dendritic cells and multiple sclerosis: disease, tolerance and therapy. 2012 , 14, 547-62	22
699	Relapsing-remitting and primary progressive MS have the same cause(s)--the neuropathologist's view: 1. 2013 , 19, 266-7	8
698	Gene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis. 2013 , 19, 1249-54	5
697	Adenosine A2A receptors in secondary progressive multiple sclerosis: a [(11)C]TMSX brain PET study. 2013 , 33, 1394-401	71
696	Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. 2013 , 3, 130181	215
695	Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. 2013 , 136, 2305-17	85
694	Methodological approach from the Best Overall Team in the sbv IMPROVER Diagnostic Signature Challenge. 2013 , 1, 217-227	9
693	Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures. 2013 , 2013, 726954	79
692	Role of microglia in CNS autoimmunity. 2013 , 2013, 208093	132
691	Which immune cells matter? The immunopathogenesis of multiple sclerosis. 2013 , 33, 283-306	32
690	Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. 2014 , 6, 171	138
689	The Peripheral Network between Oxidative Stress and Inflammation in Multiple Sclerosis. 2014 , 12, 351-363	3
688	Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. 2014 , 82, 1499-507	91
687	CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis. 2014 , 1, e21	15
686	[Introduction. Multiple sclerosis]. 2014 , 143 Suppl 3, 1-2	
685	Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?. 2014 , 1, e38	8

684	Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. 2014 , 85, 1386-95	201
683	Pervasive axonal transport deficits in multiple sclerosis models. 2014 , 84, 1183-90	119
682	Relationship between subjective and objective cognitive performance in multiple sclerosis. 2014 , 130, 319-27	14
681	Congress report of the 2014 American Academy of Neurology annual meeting. 2014 , 5, 391-399	1
680	Relapsing and progressive forms of multiple sclerosis: insights from pathology. 2014 , 27, 271-8	131
679	Positive or negative involvement of heat shock proteins in multiple sclerosis pathogenesis: an overview. 2014 , 73, 1092-106	13
678	Neurodegeneration and Multiple Sclerosis. 2014 , 227-245	5
677	Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. 2014 , 2014, 961863	39
676	Cognitive performance profile in different phenotypes of MS with cognitive complaints. 2014 , 3, 463-72	12
675	Continuous prediction of secondary progression in the individual course of multiple sclerosis. 2014 , 3, 584-92	35
674	Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis. 2014 , 79, 567-72	25
673	Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely. 2014 , 3, 555-64	51
672	Regenerative therapies for central nervous system diseases: a biomaterials approach. 2014 , 39, 169-88	184
671	Topography of brain sodium accumulation in progressive multiple sclerosis. 2014 , 27, 53-62	41
670	Neurodegenerative Diseases. 2014 ,	2
669	Myelin Oligodendrocyte Glycoprotein (MOG): An Archetypal Target for Demyelinating Autoantibodies in the Central Nervous System. 2014 , 617-627	2
668	Ten years of proteomics in multiple sclerosis. 2014 , 14, 467-80	27
667	Understanding the pharmacology of stroke and multiple sclerosis through imaging. 2014 , 14, 34-41	1

666	Multiple sclerosis: lessons from molecular neuropathology. 2014 , 262 Pt A, 2-7	87
665	Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. 2014 , 86, 257-64	33
664	Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. 2014 , 20, 179-87	163
663	Biomarkers of therapeutic response in multiple sclerosis: current status. 2014 , 18, 605-17	59
662	A unified cell biological perspective on axon-myelin injury. 2014 , 206, 335-45	59
661	The new era of multiple sclerosis therapy. 2014 , 275, 382-6	3
660	Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. 2014 , 1, 409-22	64
659	CNS neuroimmunology seen by a neuropathologist. 2014 , 170, 561-3	2
658	Astrocyte-derived retinoic acid: a novel regulator of blood-brain barrier function in multiple sclerosis. 2014 , 128, 691-703	80
657	Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions. 2014 , 62, 1125-41	65
656	Pathology of multiple sclerosis and related inflammatory demyelinating diseases. 2014 , 122, 15-58	179
655	Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. 2014 , 20, 304-12	89
654	A changing treatment landscape for multiple sclerosis: challenges and opportunities. 2014 , 275, 364-81	46
653	Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosis. 2014 , 193, 2147-56	18
652	Animal Models for Stem Cell Therapy. 2014 ,	2
651	Genetic control of nerve conduction velocity may influence multiple sclerosis phenotype. 2014 , 184, 2369-70	1
650	Mechanisms of white matter damage in multiple sclerosis. 2014 , 62, 1816-30	115
649	The role of iron in brain ageing and neurodegenerative disorders. 2014 , 13, 1045-60	811

648	Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN- γ and alpha B-crystallin. 2014 , 128, 215-29		54
647	Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. 2014 , 128, 247-66		87
646	Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2014 , 10, 225-38	15	371
645	Mitochondrial dysfunction in central nervous system white matter disorders. 2014 , 62, 1878-94		43
644	Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. 2014 , 13, 807-22		153
643	Macrophages migrate in an activation-dependent manner to chemokines involved in neuroinflammation. 2014 , 11, 23		86
642	Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review. 2014 , 54, 81-92		59
641	In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand [11 C]-PK11195. 2014 , 55, 939-44		103
640	Iron in multiple sclerosis: roles in neurodegeneration and repair. <i>Nature Reviews Neurology</i> , 2014 , 10, 459-68	15	134
639	Defining the clinical course of multiple sclerosis: the 2013 revisions. 2014 , 83, 278-86		1632
638	Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. 2014 , 383, 2213-21		283
637	Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. 2014 , 76, 231-40		42
636	B cell follicle-like structures in multiple sclerosis-with focus on the role of B cell activating factor. 2014 , 273, 1-7		30
635	Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. 2014 , 4, 182-9		125
634	The impact of microglial activation on blood-brain barrier in brain diseases. 2014 , 8, 362		302
633	Elevated levels of carbonyl proteins in cerebrospinal fluid of patients with neurodegenerative diseases. 2014 , 234, 313-7		12
632	Visual pathway neurodegeneration winged by mitochondrial dysfunction. 2015 , 2, 140-50		12
631	Immune Response in the Human Central Nervous System in Multiple Sclerosis and Stroke. 2015 , 1-19		2

630	Nrf2 in health and disease: current and future clinical implications. 2015 , 129, 989-99	85
629	Resolution of Inflammation in the Lesioned Central Nervous System. 2015 , 265-279	
628	Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial. 2015 , 2, e147	6
627	Astrocyte response to IFN- β limits IL-6-mediated microglia activation and progressive autoimmune encephalomyelitis. 2015 , 12, 79	44
626	Control of the blood-brain barrier function in cancer cell metastasis. 2015 , 107, 342-71	20
625	Polynucleotide kinase-phosphatase enables neurogenesis via multiple DNA repair pathways to maintain genome stability. 2015 , 34, 2465-80	39
624	Progressive multiple sclerosis. 2015 , 28, 237-43	46
623	Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. 2015 , 78, 710-21	307
622	. 2015 ,	1
621	Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?. 2015 , 16, 17565-88	18
620	Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases. 2015 , 35, 505-27	12
619	Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. 2015 , 9, 28	185
618	Myelin damage and repair in pathologic CNS: challenges and prospects. 2015 , 8, 35	119
617	Ageing, neuroinflammation and neurodegeneration. 2015 , 7, 189-204	30
616	Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. 2015 , 2015, 620581	115
615	Relationship between the Increased Haemostatic Properties of Blood Platelets and Oxidative Stress Level in Multiple Sclerosis Patients with the Secondary Progressive Stage. 2015 , 2015, 240918	20
614	Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis. 2015 , 2015, 725370	75
613	The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis. 2015 , 2015, 681289	31

612	Roles of CD4 and CD8 T Lymphocytes in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. 2015 , 39-52	0
611	Advances in the immunopathogenesis of multiple sclerosis. 2015 , 28, 206-19	106
610	Metabolic reprogramming of mononuclear phagocytes in progressive multiple sclerosis. 2015 , 6, 106	28
609	Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - NO. 2015 , 21, 1371-4	2
608	Are PrP(C)s involved in some human myelin diseases? Relating experimental studies to human pathology. 2015 , 359, 396-403	3
607	Cytomegalovirus: a culprit or protector in multiple sclerosis?. 2015 , 21, 16-23	40
606	Exploring the origins of grey matter damage in multiple sclerosis. 2015 , 16, 147-58	250
605	Nanomaterial applications in multiple sclerosis inflamed brain. 2015 , 10, 1-13	13
604	Promoting remyelination in multiple sclerosis: current drugs and future prospects. 2015 , 21, 541-9	55
603	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. 2015 , 21, 1431-42	18
602	The role of the cerebellum in multiple sclerosis. 2015 , 14, 364-74	34
601	Serum NSE level and disability progression in multiple sclerosis. 2015 , 350, 46-50	12
600	Expression of iron homeostasis proteins in the spinal cord in experimental autoimmune encephalomyelitis and their implications for iron accumulation. 2015 , 81, 93-107	46
599	Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFN γ /IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis. 2015 , 10, 457-67	18
598	Peripheral blood biomarkers in multiple sclerosis. 2015 , 14, 1097-110	39
597	[New therapeutic strategies for remyelination in multiple sclerosis]. 2015 , 86, 934-46	
596	IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice. 2015 , 285, 129-36	23
595	Fibroblast growth factor signalling in multiple sclerosis: inhibition of myelination and induction of pro-inflammatory environment by FGF9. 2015 , 138, 1875-93	39

594	Esclerosis múltiple. 2015 , 11, 4610-4621	4
593	The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. 2015 , 127-128, 1-22	90
592	Inefficient clearance of myelin debris by microglia impairs remyelinating processes. 2015 , 212, 481-95	283
591	Age-dependent effects on the treatment response of natalizumab in MS patients. 2015 , 21, 48-56	17
590	Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. 2015 , 273, 151-60	35
589	Imaging neuroinflammation in multiple sclerosis using TSPO-PET. 2015 , 3, 461-473	32
588	Genetic association of MiR-146a with multiple sclerosis susceptibility in the Chinese population. 2015 , 35, 281-91	37
587	Deletion of mitochondrial anchoring protects dysmyelinating shiverer: implications for progressive MS. 2015 , 35, 5293-306	26
586	Differential modulation of the juxtapanodal complex in Multiple Sclerosis. 2015 , 67, 93-103	9
585	Multimodal neurophysiological evaluation of primary progressive multiple sclerosis - An increasingly valid biomarker, with limits. 2015 , 4, 607-13	13
584	Critical role for prokineticin 2 in CNS autoimmunity. 2015 , 2, e95	20
583	Hydrogels for central nervous system therapeutic strategies. 2015 , 229, 905-16	10
582	Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. 2015 , 6, 8437	62
581	Cerebrospinal fluid proteomics in multiple sclerosis. 2015 , 1854, 746-56	21
580	Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. 2015 , 147, 123-135	158
579	[A review of multiple sclerosis (1). Presentation of a case]. 2015 , 41, 261-5	4
578	Consequences of Gut Dysbiosis on the Human Brain. 2016 ,	1
577	Epigenetics and Regenerative Medicine: Neural and Skeletal Muscle Perspectives. 2016 , 859-876	

576	Multiple Sclerosis Pathology: Inflammation Versus Neurodegeneration. 2016 , 3-13	3
575	A study of patients with aggressive multiple sclerosis at disease onset. 2016 , 12, 1907-12	9
574	mTOR in Multiple Sclerosis: The Emerging Role in the Regulation of Glial Biology. 2016 , 331-343	2
573	The Immunobiology of Multiple Sclerosis. 2016 , 180-191	2
572	The Growing Potential of Neurophysiology in Multiple Sclerosis. 2016 , 03,	
571	B-Cell Therapies in Relapsing Remitting and Primary Progressive Multiple Sclerosis: A Short Clinical Review. 2016 , 5,	
570	Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases. 2016 , 2016, 7909380	86
569	New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis. 2016 , 2016, 1973834	66
568	Protandim Protects Oligodendrocytes against an Oxidative Insult. 2016 , 5,	10
567	A Review of Multiple Sclerosis as an Infectious Syndrome. 2016 , 07,	1
566	Antibodies to the RNA-binding protein hnRNP A1 contribute to neurodegeneration in a model of central nervous system autoimmune inflammatory disease. 2016 , 13, 178	21
565	Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. 2016 , 23, 722-8	8
564	Sodium MRI of multiple sclerosis. 2016 , 29, 153-61	28
563	Gadolinium-Enhancing Lesions Lead to Decreases in White Matter Tract Fractional Anisotropy in Multiple Sclerosis. 2016 , 26, 289-95	5
562	Biochemistry of Oxidative Stress. 2016 ,	3
561	Multiple sclerosis, a treatable disease. 2016 , 16, s53-s59	49
560	Oxidative Stress and Neurodegeneration. 2016 , 309-325	
559	Regeneration strategies after the adult mammalian central nervous system injury-biomaterials. 2016 , 3, 115-22	9

558	Further understanding of the immunopathology of multiple sclerosis: impact on future treatments. 2016 , 12, 1069-89		12
557	Lactate dehydrogenase inhibition: exploring possible applications beyond cancer treatment. 2016 , 8, 713-25		19
556	Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015. 2016 , 16, 689-700		11
555	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. 2016 , 263, 1449-51		2
554	Advanced MRI and staging of multiple sclerosis lesions. <i>Nature Reviews Neurology</i> , 2016 , 12, 358-68	15	78
553	Accumulation of reactivity to MBP sensitizes TRAIL mediated oligodendrocyte apoptosis in adult sub cortical white matter in a model for human multiple sclerosis. 2016 , 31, 299-309		4
552	Absence of systemic oxidative stress and increased CSF prostaglandin F ₂ in progressive MS. 2016 , 3, e256		12
551	Neurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation. 2016 , 37, 668-679		138
550	Pathogenic inflammation in the CNS of mice carrying human PLP1 mutations. 2016 , 25, 4686-4702		16
549	Magnetic Resonance Spectroscopy of Degenerative Brain Diseases. 2016 ,		0
548	Overlaps between multiple system atrophy and multiple sclerosis: A novel perspective. 2016 , 31, 1767-1771		5
547	Sodium MRI in Multiple Sclerosis is Compatible with Intracellular Sodium Accumulation and Inflammation-Induced Hyper-Cellularity of Acute Brain Lesions. 2016 , 6, 31269		14
546	The topographical model of multiple sclerosis: A dynamic visualization of disease course. 2016 , 3, e279		84
545	Neuroprotection by central nervous system remyelination: Molecular, cellular, and functional considerations. 2016 , 94, 1411-1420		15
544	Long-term evolution of multiple sclerosis disability in the treatment era. 2016 , 80, 499-510		229
543	Inflammation severely alters thyroid hormone signaling in the central nervous system during experimental allergic encephalomyelitis in rat: Direct impact on OPCs differentiation failure. 2016 , 64, 1573-89		20
542	IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation. 2016 , 139, 1939-57		62
541	The link of inflammation and neurodegeneration in progressive multiple sclerosis. 2016 , 1,		40

540	Cause and prevention of demyelination in a model multiple sclerosis lesion. 2016 , 79, 591-604	56
539	Selective hair cell ablation and noise exposure lead to different patterns of changes in the cochlea and the cochlear nucleus. 2016 , 332, 242-57	23
538	Multiple Sclerosis and Neurodegenerative Diseases. 2016 , 63-84	3
537	Cytokine and chemokine alterations in tissue, CSF, and plasma in early presymptomatic phase of experimental allergic encephalomyelitis (EAE), in a rat model of multiple sclerosis. 2016 , 13, 291	39
536	IL411 augments CNS remyelination and axonal protection by modulating T cell driven inflammation. 2016 , 139, 3121-3136	37
535	Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study. 2016 , 16, 252	9
534	Enterococcus faecium strain L-3 and glatiramer acetate ameliorate experimental allergic encephalomyelitis in rats by affecting different populations of immune cells. 2016 , 7, 719-729	14
533	The Pharmacological Effects and Mechanism of Tripterygium wilfordii Hook F in Central Nervous System Autoimmunity. 2016 , 22, 496-502	14
532	Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study. 2016 , 22, 1154-62	33
531	Disability profile of multiple sclerosis in New Zealand. 2016 , 28, 97-101	2
530	Targeting mitochondrial function to protect against vision loss. 2016 , 20, 721-36	9
529	In vivo imaging of system xc- as a novel approach to monitor multiple sclerosis. 2016 , 43, 1124-38	19
528	Hydrogen-rich water improves neurological functional recovery in experimental autoimmune encephalomyelitis mice. 2016 , 294, 6-13	11
527	Type I/II Interferon Balance in the Regulation of Brain Physiology and Pathology. 2016 , 37, 181-192	64
526	Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis. 2016 , 291, 1-10	11
525	Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review. 2016 , 1019, 15-20	23
524	The relationship of age with the clinical phenotype in multiple sclerosis. 2016 , 22, 1750-1758	41
523	Axonal activity-dependent myelination in development: Insights for myelin repair. 2016 , 76, 2-8	9

522	Spring cleaning: time to rethink imaging research lines in MS?. 2016 , 263, 1893-902	5
521	The role of MRI in the evaluation of secondary progressive multiple sclerosis. 2016 , 16, 157-71	5
520	Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. 2016 , 12, 327-44	65
519	Dendritic cells in brain diseases. 2016 , 1862, 352-67	35
518	Morphogens and blood-brain barrier function in health and disease. 2016 , 4, e1090524	29
517	Bone marrow-derived macrophages and the CNS: An update on the use of experimental chimeric mouse models and bone marrow transplantation in neurological disorders. 2016 , 1862, 310-22	27
516	Optical Coherence Tomography in Multiple Sclerosis. 2016 ,	5
515	Antibody therapies in CNS diseases. 2017 , 120, 38-55	69
514	Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability. 2017 , 54, 2950-2960	31
513	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. 2017 , 12, 70-78	64
512	Update on disease-modifying therapies for multiple sclerosis. 2017 , 65, 883-891	77
511	Multiple sclerosis and air pollution exposure: Mechanisms toward brain autoimmunity. 2017 , 100, 23-30	30
510	Endogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis. 2017 , 17, 611-629	5
509	CXCL12/CXCR4/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases. 2017 , 23, 627-648	29
508	Therapeutic effects of human adipose tissue-derived stem cell (hADSC) transplantation on experimental autoimmune encephalomyelitis (EAE) mice. 2017 , 7, 42695	20
507	Inpatient cost analysis for treatment of myasthenia gravis. 2017 , 56, 1114-1118	6
506	Flow cytometric analysis reveals the high levels of platelet activation parameters in circulation of multiple sclerosis patients. 2017 , 430, 69-80	27
505	Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation. 2017 , 114, 2012-2017	108

504	The Pathophysiology and Clinical Presentation of Multiple Sclerosis. 2017 , 17-40	1
503	Neurodegeneration in multiple sclerosis and neuromyelitis optica. 2017 , 88, 137-145	141
502	Diffusion MRI quantifies early axonal loss in the presence of nerve swelling. 2017 , 14, 78	29
501	Sex-dependent treatment of chronic EAE with partial MHC class II constructs. 2017 , 14, 100	10
500	Oxidative Injury and Iron Redistribution Are Pathological Hallmarks of Marmoset Experimental Autoimmune Encephalomyelitis. 2017 , 76, 467-478	22
499	B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. 2017 , 309, 88-99	60
498	Multiple sclerosis: Pathology, diagnosis and treatments. 2017 , 13, 3163-3166	107
497	Systems medicine modeling for multiple sclerosis. 2017 , 3, 125-131	1
496	MIF Family Cytokines in Innate Immunity and Homeostasis. 2017 ,	2
495	Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis. 2017 , 3, 2055217317698724	14
494	C-PBR28 and F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. 2017 , 58, 1477-1482	36
493	Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. 2017 , 46, 951-971	128
492	Immunomodulatory Therapy for Multiple Sclerosis. 2017 , 713-736	
491	B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis. 2017 , 376, 280-282	19
490	Predicting Age Using Neuroimaging: Innovative Brain Ageing Biomarkers. 2017 , 40, 681-690	282
489	MIF and D-DT are potential disease severity modifiers in male MS subjects. 2017 , 114, E8421-E8429	60
488	Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. 2017 , 82, 259-270	58
487	MiR-30a Positively Regulates the Inflammatory Response of Microglia in Experimental Autoimmune Encephalomyelitis. 2017 , 33, 603-615	26

486	Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. 2017 , 7, e1171	87
485	Clinical studies and anti-inflammatory mechanisms of treatments. 2017 , 58 Suppl 3, 69-82	21
484	Characterization of naïve, memory and effector T cells in progressive multiple sclerosis. 2017 , 310, 17-25	15
483	Pathology and Pathogenesis of Progressive Multiple Sclerosis: Concepts and Controversies. 2017 , 01, E171-E181	1
482	Pathologie und Pathogenese der progredienten Multiplen Sklerose: Konzepte und Kontroversen. 2017 , 44, 476-488	3
481	Multiple sclerosis, a treatable disease . 2017 , 17, 530-536	31
480	Therapeutic effects of diosgenin in experimental autoimmune encephalomyelitis. 2017 , 313, 152-160	8
479	Olfactory dysfunction in patients with primary progressive MS. 2017 , 4, e369	10
478	Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis. 2017 , 54, 7520-7533	32
477	Imaging of microglial activation in MS using PET: Research use and potential future clinical application. 2017 , 23, 496-504	19
476	Multiple sclerosis animal models: a clinical and histopathological perspective. 2017 , 27, 123-137	117
475	Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered 'ribostasis' and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis. 2017 , 304, 56-62	6
474	The vascular adventitia: An endogenous, omnipresent source of stem cells in the body. 2017 , 171, 13-29	33
473	SIRT1 and NAD ⁺ precursors: Therapeutic targets in multiple sclerosis a review. 2017 , 304, 29-34	26
472	Kinematic gait parameters are highly sensitive measures of motor deficits and spinal cord injury in mice subjected to experimental autoimmune encephalomyelitis. 2017 , 317, 95-108	16
471	Case Studies in Multiple Sclerosis. 2017 ,	
470	Diagnosing secondary progressive multiple sclerosis. 2017 , 77-83	
469	Soluble CD40 ligand derived from serum is not correlated with early MS. 2017 , 14, 29-31	3

468	Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. 2017 , 8, 1990	31
467	L'Inflammation microscopique dans la sclérose en plaques : inflammation focale et inflammation diffuse. 2017 , 8, 197-203	
466	Thrombin generation correlates with disease duration in multiple sclerosis (MS): Novel insights into the MS-associated prothrombotic state. 2017 , 3, 2055217317747624	6
465	Kruppel-like factor 4 regulates neutrophil activation. 2017 , 1, 662-668	6
464	Central Administration of 5Z-7-Oxozeaenol Protects Experimental Autoimmune Encephalomyelitis Mice by Inhibiting Microglia Activation. 2017 , 8, 789	8
463	Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function. 2017 , 18,	44
462	A Unique TGFB1-Driven Genomic Program Links Astrocytosis, Low-Grade Inflammation and Partial Demyelination in Spinal Cord Periplaques from Progressive Multiple Sclerosis Patients. 2017 , 18,	13
461	Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients. 2017 , 8, 531	73
460	A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model. 2017 , 8, 804	18
459	Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. 2017 , 8, 577	107
458	Signes et symptômes de la sclérose en plaques. 2017 , 3-78	
457	Dynamics and heterogeneity of brain damage in multiple sclerosis. 2017 , 13, e1005757	23
456	Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. 2017 , 12, e0182462	9
455	Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability. 2017 , 17, 172	18
454	Effects of Probiotic Enterococci and Glatiramer Acetate on the Severity of Experimental Allergic Encephalomyelitis in Rats. 2017 , 47, 866-876	4
453	The early diagnosis and treatments in multiple sclerosis. 2017 , 32, 151	
452	Experimental models of cortical multiple sclerosis pathology. 2017 , 25-26, 69-74	
451	Effect of dimethyl fumarate on heme oxygenase-1 expression in experimental allergic encephalomyelitis in rats. 2017 , 55, 325-332	4

450	Novel mechanism and biomarker of chronic progressive multiple sclerosis. 2018 , 9, 25-34	1
449	Microglial activation, white matter tract damage, and disability in MS. 2018 , 5, e443	31
448	Aktuelle Therapien und Zukunftsoptionen für die progrediente Multiple Sklerose. 2018 , 20, 28-36	1
447	Possible effects of electroconvulsive therapy on refractory psychosis in primary progressive multiple sclerosis: A case report. 2018 , 38, 92-94	1
446	Disease-Modifying Treatment in Progressive Multiple Sclerosis. 2018 , 20, 12	39
445	Novel mechanisms of chronic inflammation in secondary progressive multiple sclerosis. 2018 , 9, 13-19	
444	Structural MRI Correlates of Cognitive Event-Related Potentials in Multiple Sclerosis. 2018 , 35, 399-407	2
443	Immune-cell BDNF expression in treatment-naïve relapsing-remitting multiple sclerosis patients and following one year of immunomodulation therapy. 2018 , 52, 483-489	2
442	Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization. 2018 , 9, 251	22
441	A new focal model resembling features of cortical pathology of the progressive forms of multiple sclerosis: Influence of innate immunity. 2018 , 69, 515-531	19
440	Bryostatins-1 alleviates experimental multiple sclerosis. 2018 , 115, 2186-2191	25
439	Diffusion Kurtosis Imaging Shows Similar Cerebral Axonal Damage in Patients with HIV Infection and Multiple Sclerosis. 2018 , 28, 320-327	7
438	Beneficial effect of atorvastatin-modified dendritic cells pulsed with myelin oligodendrocyte glycoprotein autoantigen on experimental autoimmune encephalomyelitis. 2018 , 29, 317-327	9
437	Multiple Sclerosis Pathology. 2018 , 8,	225
436	A potential impact of Helicobacter pylori-related galectin-3 in neurodegeneration. 2018 , 113, 137-151	19
435	A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. 2018 , 11, 391-402	23
434	Multiple Sclerosis. 2018 , 378, 169-180	921
433	Lipid biochemical changes detected in normal appearing white matter of chronic multiple sclerosis by spectral coherent Raman imaging. 2018 , 9, 1586-1595	7

432	Effective treatment of progressive MS remains elusive. 2018 , 391, 1239-1240	6
431	Multiple sclerosis. 2018 , 391, 1622-1636	698
430	The Evidence for Dietary Interventions and Nutritional Supplements as Treatment Options in Multiple Sclerosis: a Review. 2018 , 20, 8	21
429	Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. 2018 , 24, 472-480	19
428	Modulating inflammation and neuroprotection in multiple sclerosis. 2018 , 96, 927-950	23
427	Stem Cells and Other Emerging Agents as Innovative "Drugs" in Neurodegenerative Diseases: Benefits and Limitations. 2018 , 21, 123-140	7
426	Differential contribution of microglia and monocytes in neurodegenerative diseases. 2018 , 125, 809-826	47
425	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. 2018 , 167, 438-452	43
424	New Insights into Multiple Sclerosis Clinical Course from the Topographical Model and Functional Reserve. 2018 , 36, 13-25	10
423	Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?. 2018 , 24, 1543-1556	21
422	The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. 2018 , 160, 82-100	76
421	A review on nanotechnology based innovations in diagnosis and treatment of multiple sclerosis. 2018 , 4, 56-64	20
420	Progressive Forms of Multiple Sclerosis: Distinct Entity or Age-Dependent Phenomena. 2018 , 36, 163-171	28
419	Neue Therapieansätze bei progredienter Multipler Sklerose. 2018 , 1, 47-64	
418	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [F]DPA714 PET. 2018 , 15, 314	45
417	Fingolimod reduces circulating tight-junction protein levels and in vitro peripheral blood mononuclear cells migration in multiple sclerosis patients. 2018 , 8, 15371	9
416	Multiple sclerosis. 2018 , 4, 43	372
415	Targeting senescence to delay progression of multiple sclerosis. 2018 , 96, 1153-1166	24

414	Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica. 2018 , 66, 2575-2588	15
413	Serum GFAP as a biomarker for disease severity in multiple sclerosis. 2018 , 8, 14798	74
412	Multiple Sclerosis. 2018 , 25-30	
411	Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. 2018 , 19, 1212-1223	90
410	Targeting fibrin in neurodegeneration. 2018 , 19, 1149-1150	3
409	Are antioxidant parameters in serum altered in patients with relapsing-remitting multiple sclerosis treated with II-line immunomodulatory therapy?. 2018 , 52, 1083-1093	2
408	Where there is inflammation, treatment may reduce disability progression - Yes. 2018 , 24, 1808-1810	2
407	Multiple Sclerosis Pathology and its Reflection by Imaging Technologies: Introduction. 2018 , 28, 721-722	1
406	Myelin water imaging to detect demyelination and remyelination and its validation in pathology. 2018 , 28, 750-764	27
405	Basal cortisol levels and the relationship with clinical symptoms in multiple sclerosis: a systematic review. 2018 , 76, 622-634	11
404	The relationship between corticospinal tract integrity and lower-extremity strength is attenuated when controlling for age and sex in multiple sclerosis. 2018 , 1701, 171-176	2
403	The Properties of Cytokines in Multiple Sclerosis: Pros and Cons. 2018 , 356, 552-560	37
402	Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. 2018 , 115, 9773-9778	42
401	Static postural control disturbances among the different multiple sclerosis phenotypes: A Neurocom Balance Manager evaluation study. 2018 , 26, 46-51	3
400	The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. 2018 , 90, e2107-e2118	51
399	Much, if not all, of the cortical damage in MS can be attributed to the microglial cell - No. 2018 , 24, 897-899	
398	Hesperetin reduces myelin damage and ameliorates glial activation in lysolecithin-induced focal demyelination model of rat optic chiasm. 2018 , 207, 471-479	12
397	Monitoring Progressive Multiple Sclerosis with Novel Imaging Techniques. 2018 , 7, 265-285	11

396	Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. 2018 , 13, e0195891	80
395	SIRT1 and NRF2 Gene Transfer Mediate Distinct Neuroprotective Effects Upon Retinal Ganglion Cell Survival and Function in Experimental Optic Neuritis. 2018 , 59, 1212-1220	27
394	Past, Present and Future of Cell-Based Therapy in Progressive Multiple Sclerosis. 2018 , 87-132	
393	Teriflunomide attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations. 2018 , 15, 194	12
392	Shuttling Tolerogenic Dendritic Cells across the Blood-Brain Barrier the Introduction of C-C Chemokine Receptor 5 Expression Using Messenger RNA Electroporation. 2017 , 8, 1964	8
391	The Role of Astrocytes in Multiple Sclerosis. 2018 , 9, 217	140
390	Role of TFH Cells in Promoting T Helper 17-Induced Neuroinflammation. 2018 , 9, 382	34
389	Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis Treatment. 2018 , 9, 925	65
388	Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography. 2018 , 9, 181	38
387	Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes. 2018 , 19,	101
386	7Hydroxycholesterol-induced cell death, oxidative stress, and fatty acid metabolism dysfunctions attenuated with sea urchin egg oil. 2018 , 153, 210-219	11
385	Glycans as critical regulators of gut immunity in homeostasis and disease. 2018 , 333, 9-18	16
384	Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation. 2018 , 15, 121	13
383	Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis. 2018 , 5,	11
382	Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management. 2018 , 1-20	0
381	Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions. 2018 , 10, 238	60
380	Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases - Pages 109-136. 2018 , 109-136	
379	Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. 2018 , 84, 51-63	21

378	White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques. 2018 , 13, e0191131	8
377	Neuroimaging Studies Illustrate the Commonalities Between Ageing and Brain Diseases. 2018 , 40, e1700221	8
376	Immunomodulatory function of Treg-derived exosomes is impaired in patients with relapsing-remitting multiple sclerosis. 2018 , 66, 513-520	26
375	Thyroid Hormone and the White Matter of the Central Nervous System: From Development to Repair. 2018 , 106, 253-281	17
374	G-Protein-Coupled Receptor Gpr17 Expression in Two Multiple Sclerosis Remyelination Models. 2019 , 56, 1109-1123	20
373	Cortical and meningeal pathology in progressive multiple sclerosis: a new therapeutic target?. 2019 , 30, 221-232	4
372	Developmental Changes in Oligodendrocyte Genesis, Myelination, and Associated Behavioral Dysfunction in a Rat Model of Intra-generational Protein Malnutrition. 2019 , 56, 595-610	13
371	Chronic inflammation in multiple sclerosis - seeing what was always there. <i>Nature Reviews Neurology</i> , 2019 , 15, 582-593	15 46
370	Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. 2019 , 18, 905-922	137
369	Beyond the antibodies: serum metabolomic profiling of myasthenia gravis. 2019 , 15, 109	3
368	[C]PIB PET imaging can detect white and grey matter demyelination in a non-human primate model of progressive multiple sclerosis. 2019 , 35, 108-115	7
367	Reactive Oxygen Species Are Key Mediators of Demyelination in Canine Distemper Leukoencephalitis but not in Theiler's Murine Encephalomyelitis. 2019 , 20,	4
366	Human retrovirus pHEV-W envelope protein and the pathogenesis of multiple sclerosis. 2019 , 116, 14791-14793	
365	Deletion of CD38 Suppresses Glial Activation and Neuroinflammation in a Mouse Model of Demyelination. 2019 , 13, 258	19
364	Macrophage galactose-type lectin (MGL) is induced on M2 microglia and participates in the resolution phase of autoimmune neuroinflammation. 2019 , 16, 130	11
363	Siponimod in the treatment of multiple sclerosis. 2019 , 28, 1051-1057	18
362	Assessment of Mitochondrial Dysfunction in Experimental Autoimmune Encephalomyelitis (EAE) Models of Multiple Sclerosis. 2019 , 20,	8
361	Cingulate-basal ganglia-thalamo-cortical aspects of catatonia and implications for treatment. 2019 , 166, 223-252	5

360	Modification of CSF findings in multiple sclerosis in the era of rapidly expanding treatment options. 2019 , 19, 277-283	0
359	Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. 2019 , 10, 7	30
358	Combination of Cannabinoids, Δ^9 -Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways. 2019 , 10, 1921	38
357	Quetiapine has an additive effect to triiodothyronine in inducing differentiation of oligodendrocyte precursor cells through induction of cholesterol biosynthesis. 2019 , 14, e0221747	7
356	Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis. 2019 , 93, e1348-e1359	23
355	Microglial nodules provide the environment for pathogenic T cells in human encephalitis. 2019 , 137, 619-635	29
354	Highly active multiple sclerosis: An update. 2019 , 30, 215-224	34
353	Social Mind and Long-Lasting Disease: Focus on Affective and Cognitive Theory of Mind in Multiple Sclerosis. 2019 , 10, 218	21
352	Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis. 2019 , 29, 640-657	15
351	Patents on Quantitative Susceptibility Mapping (QSM) of Tissue Magnetism. 2019 , 13, 90-113	1
350	MiR-146a promotes oligodendrocyte progenitor cell differentiation and enhances remyelination in a model of experimental autoimmune encephalomyelitis. 2019 , 125, 154-162	21
349	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. 2019 , 18, 185-197	74
348	Tracking the evolution of CNS remyelinating lesion in mice with neutral red dye. 2019 , 116, 14290-14299	7
347	Sirtuins in Multiple Sclerosis: The crossroad of neurodegeneration, autoimmunity and metabolism. 2019 , 34, 47-58	12
346	Pericytes in Multiple Sclerosis. 2019 , 1147, 167-187	3
345	Multiple functional therapeutic effects of DL-3-n-butylphthalide in the cuprizone model of demyelination. 2019 , 232, 116501	3
344	Towards developing meaningful MRI biomarkers of neuroinflammation. 2019 , 97, 643-644	
343	Clozapine administration enhanced functional recovery after cuprizone demyelination. 2019 , 14, e0216113	10

342	Epidemiology and treatment of multiple sclerosis in elderly populations. <i>Nature Reviews Neurology</i> , 2019 , 15, 329-342	15	99
341	The S1P mimetic fingolimod phosphate regulates mitochondrial oxidative stress in neuronal cells. 2019 , 137, 116-130		21
340	Direct Lineage Reprogramming in the CNS. 2020 , 1212, 31-48		1
339	Curcumin Impact on Multiple Sclerosis. 2019 , 365-380		4
338	Interferon-Beta Treatment Differentially Alters TLR2 and TLR4-Dependent Cytokine Production in Multiple Sclerosis Patients. 2019 , 26, 77-83		2
337	The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis. 2019 , 137, 757-783		95
336	Amlexanox attenuates experimental autoimmune encephalomyelitis by inhibiting dendritic cell maturation and reprogramming effector and regulatory T cell responses. 2019 , 16, 52		18
335	Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. 2019 , 116, 9030-9039		93
334	Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?. 2019 , 10, 280		41
333	Cortical grey matter sodium accumulation is associated with disability and secondary progressive disease course in relapse-onset multiple sclerosis. 2019 , 90, 755-760		10
332	Bioinformatics Analyses Determined the Distinct CNS and Peripheral Surrogate Biomarker Candidates Between Two Mouse Models for Progressive Multiple Sclerosis. 2019 , 10, 516		5
331	Non-invasive MRI windows to neuroinflammation. 2019 , 403, 1-3		2
330	Inflammation-induced endothelial to mesenchymal transition promotes brain endothelial cell dysfunction and occurs during multiple sclerosis pathophysiology. 2019 , 10, 45		22
329	Microglia pre-activation and neurodegeneration precipitate neuroinflammation without exacerbating tissue injury in experimental autoimmune encephalomyelitis. 2019 , 7, 14		8
328	Immunoregulatory Effect of Koumine on Nonalcoholic Fatty Liver Disease Rats. 2019 , 2019, 8325102		8
327	Natalizumab treatment reduces microglial activation in the white matter of the MS brain. 2019 , 6, e574		20
326	Diagnosis and management of secondary-progressive multiple sclerosis: time for change. 2019 , 9, 301-317		10
325	[New therapeutic approaches in progressive multiple sclerosis]. 2019 , 87, 653-671		0

324	Meningeal inflammation changes the balance of TNF signalling in cortical grey matter in multiple sclerosis. 2019 , 16, 259	36
323	Identification of novel non-myelin biomarkers in multiple sclerosis using an improved phage-display approach. 2019 , 14, e0226162	8
322	Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1. 2019 , 15, 478-492	55
321	Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. 2018 , 9, 3116	187
320	Targeting microglia attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations. 2019 , 67, 277-290	10
319	Reactive astrocytes in multiple sclerosis impair neuronal outgrowth through TRPM7-mediated chondroitin sulfate proteoglycan production. 2019 , 67, 68-77	15
318	Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. 2019 , 27, 232-238	15
317	Blood lead levels and multiple sclerosis: A case-control study. 2019 , 27, 151-155	10
316	Eomes-expressing T-helper cells as potential target of therapy in chronic neuroinflammation. 2019 , 130, 104348	2
315	Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study. 2019 , 29, 52-61	15
314	Inflammation and mitochondrial dysfunction: A vicious circle in neurodegenerative disorders?. 2019 , 710, 132931	90
313	Neuroimaging Techniques to Assess Inflammation in Multiple Sclerosis. 2019 , 403, 4-16	31
312	Immunology of oligodendrocyte precursor cells in vivo and in vitro. 2019 , 331, 28-35	7
311	Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis. 2019 , 331, 11-27	20
310	Does Resetting the Immune System Fix Multiple Sclerosis?. 2020 , 47, 1-10	4
309	Clinical and MRI efficacy of sc IFN β 1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. 2020 , 267, 64-75	1
308	Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. 2020 , 37, 101452	21
307	The Effect of Abnormal Iron Metabolism on Osteoporosis. 2020 , 195, 353-365	19

306	Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis. 2020 , 22, 73-80	0
305	Response to oxidative stress of peripheral blood mononuclear cells from multiple sclerosis patients and healthy controls. 2020 , 25, 81-91	3
304	The P2X receptor tracer [C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. 2020 , 47, 379-389	30
303	Cell Biology and Translational Medicine, Volume 6. 2020 ,	
302	Differential effects of glucose deprivation on the survival of fetal versus adult neural stem cells-derived oligodendrocyte precursor cells. 2020 , 68, 898-917	9
301	Microglia as therapeutic target in central nervous system disorders. 2020 , 144, 102-118	10
300	Air Pollution-Related Brain Metal Dyshomeostasis as a Potential Risk Factor for Neurodevelopmental Disorders and Neurodegenerative Diseases. 2020 , 11, 1098	2
299	A Score Based on NFL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course. 2020 , 11, 608	11
298	Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases. 2020 , 10,	28
297	State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. 2020 , 9, 281-300	2
296	Efficacy of Sulforaphane in Neurodegenerative Diseases. 2020 , 21,	26
295	Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?. 2020 , 11, 607766	6
294	Exploring the Use of Dimethyl Fumarate as Microglia Modulator for Neurodegenerative Diseases Treatment. 2020 , 9,	9
293	Targeting Endocannabinoid Metabolism: an Arrow with Multiple Tips Against Multiple Sclerosis. 2020 , 15, 1985-2003	0
292	iPS-Derived Early Oligodendrocyte Progenitor Cells from SPMS Patients Reveal Deficient In Vitro Cell Migration Stimulation. 2020 , 9,	5
291	The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children. 2020 , 8, 439	
290	Idebenone does not inhibit disability progression in primary progressive MS. 2020 , 45, 102434	5
289	Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis. 2020 , 11, 4071	12

288	CSF1R signaling is a regulator of pathogenesis in progressive MS. 2020 , 11, 904	27
287	Beyond Alzheimer's disease: Can bilingualism be a more generalized protective factor in neurodegeneration?. 2020 , 147, 107593	7
286	Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trial. 2020 , 2, e000060	6
285	Detection of Monocyte/Macrophage and Microglia Activation in the TMEV Model of Chronic Demyelination Using USPIO-Enhanced Ultrahigh-Field Imaging. 2020 , 30, 769-778	0
284	The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. 2020 , 39, 3223-3235	19
283	Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis. 2020 , 10,	2
282	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. 2020 , 7,	11
281	Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. 2020 , 117, 22402-22412	49
280	Gray Matter Matters: A Longitudinal Magnetic Resonance Voxel-Based Morphometry Study of Primary Progressive Multiple Sclerosis. 2020 , 11, 581537	4
279	Prognostic value of odor identification impairment in multiple sclerosis: 10-Years follow-up. 2020 , 46, 102486	3
278	Diffusion basis spectrum imaging provides insights into MS pathology. 2020 , 7,	13
277	Concentrations of toxic metals and essential trace elements vary among individual neurons in the human locus ceruleus. 2020 , 15, e0233300	9
276	The window of opportunity for treatment of progressive multiple sclerosis. 2020 , 33, 262-270	14
275	IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis. 2020 , 17, 143	15
274	The Role of Optical Coherence Tomography in Differential Diagnosis of Multiple Sclerosis and Autoimmune Connective Tissue Diseases with CNS Involvement. 2020 , 9,	1
273	Effects of long-term administration of Multi-Strain Probiotic on circulating levels of BDNF, NGF, IL-6 and mental health in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. 2020 , 1-12	16
272	Oligodendrocytes Provide Antioxidant Defense Function for Neurons by Secreting Ferritin Heavy Chain. 2020 , 32, 259-272.e10	37
271	Proteomic examination of the neuroglial secretome: lessons for the clinic. 2020 , 17, 207-220	3

270	Altered secretory and neuroprotective function of the choroid plexus in progressive multiple sclerosis. 2020 , 8, 35	15
269	IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis. 2020 , 14, 120	8
268	Aging, Cellular Senescence, and Progressive Multiple Sclerosis. 2020 , 14, 178	18
267	Exercise modulates the levels of growth inhibitor genes before and after multiple sclerosis. 2020 , 341, 577172	4
266	T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis. 2020 , 9,	51
265	Chicken-or-egg question: Which came first, extracellular vesicles or autoimmune diseases?. 2020 , 108, 601-616	10
264	Quantitative Serum Proteomic Study Reveals that Fibrinogen-Related Proteins May Participate in the Pathophysiological Process of Simple Febrile Convulsion. 2020 , 31, 666-674	1
263	Early astragaloside IV administration attenuates experimental autoimmune encephalomyelitis in mice by suppressing the maturation and function of dendritic cells. 2020 , 249, 117448	10
262	White Matter Diseases. 2020 ,	1
261	Vigorous cool room treadmill training to improve walking ability in people with multiple sclerosis who use ambulatory assistive devices: a feasibility study. 2020 , 20, 33	9
260	Inflammation of the choroid plexus in progressive multiple sclerosis: accumulation of granulocytes and T cells. 2020 , 8, 9	15
259	Dynamic Balance of Microglia and Astrocytes Involved in the Remyelinating Effect of Ginkgolide B. 2019 , 13, 572	9
258	Microglia in Multiple Sclerosis: Friend or Foe?. 2020 , 11, 374	53
257	Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation. 2020 , 21, 513-524	51
256	Siponimod (BAF312) Activates Nrf2 While Hampering NFB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration. 2020 , 11, 635	24
255	Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring. 2020 , 20, 747-769	6
254	Piperine ameliorated memory impairment and myelin damage in lyssolecithin induced hippocampal demyelination. 2020 , 253, 117671	8
253	Activity-Dependent Neurodegeneration and Neuroplasticity of Auditory Neurons Following Conductive Hearing Loss in Adult Mice. 2021 , 41, 31-42	4

252	Acute motor deficit and subsequent remyelination-associated recovery following internal capsule demyelination in mice. 2021 , 156, 917-928	7
251	Overexpression of the ubiquitin-editing enzyme A20 in the brain lesions of Multiple Sclerosis patients: moving from systemic to central nervous system inflammation. 2021 , 31, 283-296	4
250	Cuprizone-induced demyelination triggers a CD8-pronounced T cell recruitment. 2021 , 69, 925-942	9
249	Signaling by cGAS-STING in Neurodegeneration, Neuroinflammation, and Aging. 2021 , 44, 83-96	21
248	Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. 2021 , 96, e111-e120	11
247	Cuprizone-Dependent De/Remyelination Responses and Functional Correlates in Mouse Strains Adopted to Model Relapsing, Chronic and Progressive Experimental Autoimmune Encephalomyelitis. 2021 , 39, 658-666	
246	Encyclopedia of Molecular Pharmacology. 2021 , 1-6	
245	Dynamic glial response and crosstalk in demyelination-remyelination and neurodegeneration processes. 2021 , 16, 1359-1368	3
244	Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies. 2021 , 31, 102734	
243	The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis. 2021 , 14,	0
242	Translational Value of CSF and Blood Markers of Autoimmunity and Neurodegeneration. 2021 , 77-86	
241	Astrocytes lure CXCR2-expressing CD4 T cells to gray matter via TAK1-mediated chemokine production in a mouse model of multiple sclerosis. 2021 , 118,	3
240	CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes. 2021 , 11, 4132	2
239	Engine Failure in Axo-Myelinic Signaling: A Potential Key Player in the Pathogenesis of Multiple Sclerosis. 2021 , 15, 610295	2
238	Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis. 2021 , 13, e13246	
237	Clinical and radiological features of MS, NMOSD, and MOGAD, and evolution of the diagnostic processes in Thailand. 2021 , 9, 282-291	0
236	[MSProDiscuss - Development of a Digital Anamnesis Tool to Identify Disease Progression in Multiple Sclerosis]. 2021 , 89, 374-381	1
235	Whole Brain Adiabatic T and Relaxation Along a Fictitious Field Imaging in Healthy Volunteers and Patients With Multiple Sclerosis: Initial Findings. 2021 , 54, 866-879	

234	[Disease-modifying treatment of secondary progressive multiple sclerosis]. 2021 , 92, 1052-1060	
233	PARP overactivation in neurological disorders. 2021 , 48, 2833-2841	1
232	Neuron-Oligodendrocyte Interactions in the Structure and Integrity of Axons. 2021 , 9, 653101	14
231	Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis. 2021 , 96, e1865-e1875	7
230	Multiple Sclerosis. 1-43	
229	Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function. 2021 , 186, 114465	9
228	Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications. 2021 , 21, 26	10
227	[Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis]. 2021 , 92, 1293-1301	0
226	MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes. 2021 , 27, 1002-1004	1
225	Deciphering Multiple Sclerosis Progression. 2021 , 12, 608491	7
224	Astrocytes in Multiple Sclerosis-Essential Constituents with Diverse Multifaceted Functions. 2021 , 22,	4
223	Clozapine Regulates Microglia and Is Effective in Chronic Experimental Autoimmune Encephalomyelitis. 2021 , 12, 656941	5
222	Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease. 2021 , 12, 672455	4
221	Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. 2021 , 50, 102778	3
220	Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis. 2021 , 53, 102319	4
219	Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation. 2021 , 206, 2338-2352	1
218	Immunomodulatory Therapy with Glatiramer Acetate Reduces Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Experimental Autoimmune Encephalomyelitis.	0
217	Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey. 2021 , 50, 102858	0

216	Assessment of the genetic contribution to brain magnetic resonance imaging lesion load and atrophy measures in multiple sclerosis patients. 2021 , 28, 2513-2522	0
215	A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers. 2021 , 51, 102861	1
214	Secondary Progressive Multiple Sclerosis: New Insights. 2021 , 97, 378-388	14
213	The Role of B Cells in Primary Progressive Multiple Sclerosis. 2021 , 12, 680581	3
212	Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players. 2021 , 26,	4
211	Flavonoids, the compounds with anti-inflammatory and immunomodulatory properties, as promising tools in multiple sclerosis (MS) therapy: A systematic review of preclinical evidence. 2021 , 95, 107562	6
210	Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?. 2021 , 78, 787-788	0
209	The Involvement of Lactosylceramide in Central Nervous System Inflammation Related to Neurodegenerative Disease. 2021 , 13, 691230	1
208	Stem Cell Therapies for Progressive Multiple Sclerosis. 2021 , 9, 696434	5
207	Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection. 2021 , 58, 5090-5111	3
206	Social cognition in multiple sclerosis and its subtypes: A meta-analysis. 2021 , 52, 102973	7
205	Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse. 2021 , 356, 577582	
204	Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study. 2021 , 12, 681386	1
203	Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. 2021 , 1	1
202	Optical Coherence Tomography and Visual Evoked Potentials as Prognostic and Monitoring Tools in Progressive Multiple Sclerosis. 2021 , 15, 692599	4
201	Astroglial and Microglial Purinergic P2X7 Receptor as a Major Contributor to Neuroinflammation during the Course of Multiple Sclerosis. 2021 , 22,	5
200	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. 2021 , 97, e1334-e1342	2
199	Gray matter blood-brain barrier water exchange dynamics are reduced in progressive multiple sclerosis. 2021 , 31, 1111-1118	0

198	The efficacy of probiotics in experimental autoimmune encephalomyelitis (an animal model for MS): a systematic review and meta-analysis. 2021 , 73, 408-417	0
197	Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.	0
196	Understanding Abnormal c-JNK/p38MAPK Signaling Overactivation Involved in the Progression of Multiple Sclerosis: Possible Therapeutic Targets and Impact on Neurodegenerative Diseases. 2021 , 39, 1630-1650	2
195	Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy. 2021 , 10,	6
194	Metformin Therapy Attenuates Pro-inflammatory Microglia by Inhibiting NF- κ B in Cuprizone Demyelinating Mouse Model of Multiple Sclerosis. 2021 , 39, 1732-1746	1
193	Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis. 2021 , 358, 577650	0
192	Irisin levels in the serum and cerebrospinal fluid of patients with multiple sclerosis and the expression and distribution of irisin in experimental autoimmune encephalomyelitis. 2021 , 206, 208-215	1
191	Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis. 2021 , 54, 103086	1
190	Dysfunction of oligodendrocyte inwardly rectifying potassium channel in a rat model of amyotrophic lateral sclerosis. 2021 , 54, 6339-6354	0
189	Identification of immune-associated gene signature and immune cell infiltration related to overall survival in progressive multiple sclerosis. 2021 , 55, 103188	0
188	Physiopathologie et classification des neuropathies inflammatoires. 2021 , 205, 926-936	
187	Mesenchymal stem cell-based therapy in a mouse model of experimental autoimmune encephalomyelitis (EAE). 2014 , 1213, 303-19	15
186	Cannabinoid-Based Medicines and Multiple Sclerosis. 2021 , 1264, 111-129	6
185	MR Spectroscopy in Multiple Sclerosis. 2016 , 151-177	2
184	Extrinsic Factors Driving Oligodendrocyte Lineage Cell Progression in CNS Development and Injury. 2020 , 45, 630-642	11
183	Mapping microglia and astrocytes activation in vivo using diffusion MRI.	5
182	Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years.	1
181	Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury. 2020 , 5,	14

180	Electroconvulsive stimulation attenuates chronic neuroinflammation. 2020 , 5,	7
179	Microglia ablation alleviates myelin-associated catatonic signs in mice. 2018 , 128, 734-745	56
178	Key roles for lipid mediators in the adaptive immune response. 2018 , 128, 2724-2731	35
177	Progressive Multiple Sclerosis. 2016 , 22, 785-98	6
176	Progressive Multiple Sclerosis. 2019 , 25, 736-752	10
175	Phases and Phenotypes of Multiple Sclerosis. 2019 , 25, 636-654	15
174	Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS. 2021 , 8,	3
173	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. 2021 , 96, e783-e797	18
172	Novel somatic single nucleotide variants within the RNA binding protein hnRNP A1 in multiple sclerosis patients. 2014 , 3, 132	10
171	Novel somatic single nucleotide variants within the RNA binding protein hnRNP A1 in multiple sclerosis patients. 2014 , 3, 132	13
170	Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. 2015 , 10, e0122048	39
169	Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. 2015 , 10, e0123824	21
168	Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?. 2015 , 10, e0133392	52
167	Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance. 2017 , 12, e0181758	41
166	Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner. 2017 , 12, e0187215	10
165	Novel Approaches of Oxidative Stress Mechanisms in the Multiple Sclerosis Pathophysiology and Therapy. 155-171	5
164	Protective Effects of the Caffeine Against Neurodegenerative Diseases. 2019 , 26, 5137-5151	12
163	Early Diagnosis of Multiple Sclerosis Based on Optical and Electrochemical Biosensors: Comprehensive Perspective. 2020 , 16, 557-569	9

162	A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. 2020 , 22, e16932	20
161	Cytokine Modulatory Effects of Sesamum Indicum Seeds Oil Ameliorate Mice with Experimental Autoimmune Encephalomyelitis. 2017 , 1, 086-093	1
160	Paraoxonase Role in Human Neurodegenerative Diseases. 2020 , 10,	7
159	Levels of leukocyte oxidative DNA damage (8-OHdG), serum coenzyme Q10 and lipid peroxidation in the formation attacks of patients with multiple sclerosis. 2017 , 9, 601-607	1
158	Relationship between miR-155 and miR-146a polymorphisms and susceptibility to multiple sclerosis in an Egyptian cohort. 2020 , 12, 276-284	4
157	Structure and function of the contactin-associated protein family in myelinated axons and their relationship with nerve diseases. 2017 , 12, 1551-1558	20
156	Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches. 2018 , 13, 1871-1874	13
155	Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis. 2020 , 15, 1039-1040	1
154	Clinical and Imaging Features of Patients With Encephalitic Symptoms and Myelin Oligodendrocyte Glycoprotein Antibodies. 2021 , 12, 722404	2
153	Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression. 2021 , 1	2
152	Role of SIRT3 and Mitochondrial Dysfunction in Neurodegeneration. 2022 , 99-120	
151	Astrocytic YAP prevents the demyelination through promoting expression of cholesterol synthesis genes in experimental autoimmune encephalomyelitis. 2021 , 12, 907	3
150	The Cross Talk between Underlying Mechanisms of Multiple Sclerosis and Epilepsy May Provide New Insights for More Efficient Therapies. 2021 , 14,	1
149	The effect of sodium channels on neurological/neuronal disorders: A systematic review. 2021 , 81, 669-685	0
148	Memantine Modulates Oxidative Stress in the Rat Brain following Experimental Autoimmune Encephalomyelitis. 2021 , 22,	0
147	CHAPTER 7:Multiple Sclerosis. 2013 , 163-185	
146	White Matter Damage in Multiple Sclerosis. 2014 , 405-429	
145	Gut Microbiota and Central Nervous System Condemned to Understand Each Other: Their Role in Multiple Sclerosis. 2014 , 1,	

- 144 Responses of multiple sclerosis via IL-6/ effectiveness of action. **2015**, 3, 188-205
- 143 Progressive Multiple Sclerosis (SP and PP MS). **2016**, 135-150
- 142 Remyelination in multiple sclerosis, neuroprotective potential of glatiramer acetate and laquinimode. **2016**, 17, 60-62
- 141 Role of MIF in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. **2017**, 97-107
- 140 Monoclonal Antibody Therapy and Long-term Outcomes in Multiple Sclerosis [The Challenge of Treatment Optimisation. **2018**, 13, 78
- 139 Response to letter to the editors. **2018**, 22, 86
- 138 [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis]. **2019**, 119, 110-119 1
- 137 Vigorous cool room treadmill training to improve walking ability in people with Multiple Sclerosis who use ambulatory assistive devices: A feasibility study..
- 136 New possibilities for the therapy of secondary progressive multiple sclerosis. **2019**, 11, 125-129 2
- 135 Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas/Casp8/Bid-axis. 1
- 134 The effect of mobile-based self-care program on balance of people with Multiple Sclerosis. **2020**, 7, 33-43
- 133 Understanding the role of the blood brain barrier and peripheral inflammation on behavior and pathology on ongoing confined cortical lesions.. **2022**, 57, 103346 0
- 132 Multiple Sclerosis. **2020**, 1-35
- 131 Vigorous cool room treadmill training to improve walking ability in people with Multiple Sclerosis who use ambulatory assistive devices: A feasibility study..
- 130 [New tools for early detection of multiple sclerosis progression: MSProDiscuss questionnaire]. **2020**, 120, 43-47 1
- 129 Analysis of probable predictors of aggressive multiple sclerosis. **2020**, 18, 127-135
- 128 Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase 1, randomized, blinded, placebo-controlled trial.
- 127 Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. *Nature Reviews Neurology*, **2021**, 15 3

126	¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis.. 2022 , 57, 103368	4
125	PET Imaging in Multiple Sclerosis. 2021 , 893-916	1
124	Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations. 2016 , 33, 28-34	4
123	Lower leg electromyography activation during gait initiation in multiple sclerosis patients. 2021 , 23, 556-562	
122	Demyelinating Disease. 2022 , 617-620	
121	Versatile Role of Prokineticins and Prokineticin Receptors in Neuroinflammation. 2021 , 9,	0
120	Encyclopedia of Molecular Pharmacology. 2021 , 1017-1022	
119	Rutin Exerts Anti-Oxidant Effects in H ₂ O ₂ -Induced Microglia Oxidative Stress.	
118	Plant-derived compounds, vitagens, vitagenes and mitochondrial function. 2022 , 100287	1
117	Attack of the Clones: Microglia in Health and Disease.. 2022 , 16, 831747	1
116	Overview of Polyamines as Nutrients for Human Healthy Long Life and Effect of Increased Polyamine Intake on DNA Methylation.. 2022 , 11,	1
115	Hemodynamic Alterations in Multiple Sclerosis.	
114	Nutrient-sensing amyloid metastasis.. 2022 ,	1
113	Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.. 2022 , 19, 45	1
112	Microglia and macrophages in central nervous systems. 2022 , 185-208	
111	Recent Advances in Application of Dietary Polyphenols to Treat Age-Related Neurological Disorders. 2022 , 79-100	
110	Current status and future opportunities in modeling Multiple Sclerosis clinical characteristics.	0
109	Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.. 2022 , 13524585211073761	0

108	BSDE: Barycenter Single-Cell Differential Expression for Case-Control Studies.. 2022,	0
107	Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells.. 2022,	1
106	Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair.. 2022, 1	1
105	Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review.. 2022, 1	1
104	Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing-Remitting Multiple Sclerosis Patients.. 2022,	1
103	Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.. 2022, 13, 868525	0
102	Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination.. 2022, 1	0
101	Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.. 2022,	2
100	The role of sex and pregnancy in multiple sclerosis: what do we know and what should we do?. 2022	0
99	Acetyl-11-keto-Eboswellic acid improves clinical symptoms through modulation of Nrf2 and NF- κ B pathways in SJL/J mouse model of experimental autoimmune encephalomyelitis.. 2022, 107, 108703	0
98	Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review.. 2021, 13524585211066598	
97	The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis.. 2021, 23,	0
96	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. 2021,	3
95	Together from the start: A transdiagnostic framework for early dyadic interventions for neurodegenerative diseases.. 2022,	0
94	White Matter. 283-310	
93	Data_Sheet_1.docx. 2019,	
92	Image_1.PDF. 2018,	
91	Table_1.PDF. 2018,	

90	Image_1.TIF. 2020 ,	
89	Image_2.TIF. 2020 ,	
88	Image_3.TIF. 2020 ,	
87	Data_Sheet_1.docx. 2020 ,	
86	Data_Sheet_2.docx. 2020 ,	
85	Image_1.TIF. 2019 ,	
84	Image_2.TIF. 2019 ,	
83	Image_3.TIF. 2019 ,	
82	Table_1.DOCX. 2019 ,	
81	Table_2.DOCX. 2019 ,	
80	Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients.. 2022 ,	o
79	Proteomics in Multiple Sclerosis: The Perspective of the Clinician.. 2022 , 23,	o
78	Current Status and Future Opportunities in Modeling Clinical Characteristics of Multiple Sclerosis. 2022 , 13,	o
77	A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.	o
76	RGMa Participates in the BloodBrain Barrier Dysfunction Through BMP/BMPR/YAP Signaling in Multiple Sclerosis. 2022 , 13,	o
75	Mapping microglia and astrocyte activation in vivo using diffusion MRI. 2022 , 8,	o
74	Specialized pro-resolving mediators as modulators of immune responses. 2022 , 101605	2
73	Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action.	1

72	Translational regulation of TFH cell differentiation and autoimmune pathogenesis. 2022 , 8,	1
71	A new advanced MRI biomarker for remyelinated lesions in Multiple Sclerosis.	1
70	Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response. 2022 , 11, 1959	1
69	Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis. jnnp-2022-329221	1
68	Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications. 2022 , 4,	3
67	Grey matter atrophy in patients with benign multiple sclerosis.	0
66	βAdrenoceptor Blockade Moderates Neuroinflammation in Male and Female EAE Rats and Abrogates Sexual Dimorphisms in the Major Neuroinflammatory Pathways by Being More Efficient in Males.	0
65	Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE) systematic review protocol. 2022 , 11,	0
64	Quercetin as a JAK/STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases. 2022 , 27,	2
63	Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age. 2022 , 82, 104179	0
62	Multivoxel 1H-mr spectroscopy as a potential diagnostic tool in the complex diagnosis of multiple sclerosis type conversion: a case report. 2022 , 13, 81-84	0
61	Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery. 2022 , 23, 8418	1
60	Divergent complement system activation in two clinically distinct murine models of multiple sclerosis. 13,	0
59	Microglia Contributes to BAF-312 Effects on Blood-Brain Barrier Stability. 2022 , 12, 1174	0
58	Progressive Multiple Sclerosis. 2022 , 28, 1083-1103	0
57	Epidemiology and Pathophysiology of Multiple Sclerosis. 2022 , 28, 988-1005	1
56	Ameliorative effects of acetyl-L-carnitine on corpus callosum and functional recovery in demyelinated mouse model. 1-11	0
55	Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. 135245852211140	1

- 54 Protective effects of Herbal Compound (IM253) on the inflammatory responses and oxidative stress in a mouse model of multiple sclerosis. **2022**, 67, 104076
- 53 Exploring in vivo lesion myelination dynamics: Longitudinal Myelin Water Imaging in early Multiple Sclerosis. **2022**, 36, 103192
- 52 Immunomodulatory peptidomimetics for multiple sclerosis therapy: The story of glatiramer acetate (Copaxone). **2022**, 507-520
- 51 Transcriptional abnormalities in induced pluripotent stem cell-derived oligodendrocytes of individuals with primary progressive multiple sclerosis. 16,
- 50 Heart rate variability and fatigue in MS: two parallel pathways representing disseminated inflammatory processes?.
- 49 Astrocytes show increased levels of Ero1 β in multiple sclerosis and its experimental autoimmune encephalomyelitis animal model.
- 48 Astrocytic SARM1 promotes neuroinflammation and axonal demyelination in experimental autoimmune encephalomyelitis through inhibiting GDNF signaling. **2022**, 13,
- 47 MHC class I and MHC class II reporter mice enable analysis of immune oligodendroglia in mouse models of multiple sclerosis.
- 46 Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients. 135245852211222
- 45 Neuroprotective Effect of Vesatolimod in an Experimental Autoimmune Encephalomyelitis Mice Model.
- 44 Interleukin 22 and its association with neurodegenerative disease activity. 13,
- 43 Epstein-Barr virus, interleukin-10 and multiple sclerosis: A ménage à trois. 13,
- 42 N-acetyl cysteine as a neuroprotective agent in progressive multiple sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial. **2022**, 122, 106941
- 41 Long-term effect of siponimod on MRI outcomes in patients with secondary-progressive multiple sclerosis. **2022**, 23, 296-303
- 40 Neutrophil Nanovesicle Protects against Experimental Autoimmune Encephalomyelitis through Enhancing Myelin Clearance by Microglia.
- 39 Diagnosis and treatment of progressive multiple sclerosis: A position paper.
- 38 Chronic experimental autoimmune encephalomyelitis is an excellent model to study neuroaxonal degeneration in multiple sclerosis. 15,
- 37 A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis. **2022**, 10, 2604

- 36 Exogenous Antioxidants in Remyelination and Skeletal Muscle Recovery. **2022**, 10, 2557 ○
- 35 Tau seeding in cases of multiple sclerosis. **2022**, 10, ○
- 34 Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. **2022**, 2022, ○
- 33 Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve. **2022**, 12, ○
- 32 Characterizing microglial gene expression in a model of secondary progressive multiple sclerosis. 1
- 31 Facial emotion impairment in multiple sclerosis is linked to modifying observation strategies of emotional faces. **2023**, 69, 104439 ○
- 30 T follicular helper cells in autoimmune diseases. **2023**, 134, 102976 ○
- 29 Is there any association between dietary inflammatory index and quality of life? A systematic review. 9, 1
- 28 Emerging point-of-care autologous cellular therapy using adipose-derived stromal vascular fraction for neurodegenerative diseases. **2022**, 12, ○
- 27 Myelinodegeneration vs. Neurodegeneration in MS Progressive Forms. **2023**, 24, 1596 ○
- 26 Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease. **2023**, 37, 69-92 1
- 25 Synapse Dysfunctions in Multiple Sclerosis. **2023**, 24, 1639 ○
- 24 Oxidative stress in multiple sclerosisEmerging imaging techniques. 13, ○
- 23 FNDC5/irisin mediates hallmark brain alterations and cognitive impairment in ´acute intestinal injury/disease. ○
- 22 Therapeutic potential of blocking GAPDH nitrosylation with CGP3466b in experimental autoimmune encephalomyelitis. 13, ○
- 21 High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis. 14, ○
- 20 Repurposing of Minocycline, a Tetracycline Antibiotic, for Neurodegenerative Disorders. **2023**, 615-654 ○
- 19 IL-10-providing B´cells govern pro-inflammatory activity of macrophages and microglia in CNS autoimmunity. **2023**, 145, 461-477 ○

- 18 Immunomodulatory therapy with glatiramer acetate reduces endoplasmic reticulum stress and mitochondrial dysfunction in experimental autoimmune encephalomyelitis. **2023**, 13,
- 17 Healthier living with MS: The key role of self-efficacy and emotion regulation. **2023**, 73, 104608
- 16 Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression. **2023**, 225, 107612
- 15 Specific alterations in NKG2D+ T lymphocytes in relapsing-remitting and progressive multiple sclerosis patients. **2023**, 71, 104542
- 14 Pharmacological treatment promoting remyelination enhances motor function after internal capsule demyelination in mice. **2023**, 164, 105505
- 13 Brain evolution and the meaning of catatonia - An update. **2023**,
- 12 Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo. **2023**, 13, 376
- 11 Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis. **2023**, 24, 4375
- 10 Glia Connect Inflammation and Neurodegeneration in Multiple Sclerosis. **2023**, 39, 466-478
- 9 Upregulation of C-X-C motif chemokine 12 in the spinal cord alleviated the symptoms of experimental autoimmune encephalomyelitis in Lewis rats. 17,
- 8 FGF/FGFR system in the central nervous system demyelinating disease: Recent progress and implications for multiple sclerosis.
- 7 The Tryptophan-Kynurenine Metabolic System Is Suppressed in Cuprizone-Induced Model of Demyelination Simulating Progressive Multiple Sclerosis. **2023**, 11, 945
- 6 Carnosine synthase deficiency aggravates neuroinflammation in multiple sclerosis.
- 5 The HeartBrain Interplay in Multiple Sclerosis from Pathophysiology to Clinical Practice: A Narrative Review. **2023**, 10, 153
- 4 THE ROLE OF MRI IN DIFFERENTIATING DEMYELINATING AND INFLAMMATORY (NOT INFECTIOUS) MYELOPATHIES. **2023**,
- 3 The Use of Stem Cells as a Potential Treatment Method for Selected Neurodegenerative Diseases: Review.
- 2 Cycling in primary progressive multiple sclerosis (CYPRO): study protocol for a randomized controlled superiority trial evaluating the effects of high-intensity interval training in persons with primary progressive multiple sclerosis. **2023**, 23,
- 1 SARM1 promotes the neuroinflammation and demyelination through IGF2BP2 / NF- κ B pathway in experimental autoimmune encephalomyelitis mice. **2023**, 238,

